WASHINGTON, Jan. 24, 2017 /PRNewswire/ -- At the CASSS CMC
Strategy Forum and WCBP 2017 (www.casss.org), Bruker today
announced the release of new Biopharma Compass 2.0 (BPC 2.0)
software that automates biopharmaceutical characterization
workflows for high resolution mass spectrometry. The BPC 2.0
solution is unique and more comprehensive in scope, as it unifies
data acquired from the two most relevant and perfectly
complementary mass spectrometry methods for the characterization of
biologics, MALDI-TOF/TOF and ESI-UHR-QTOF. BPC 2.0 offers a new 3D
feature finder, supports 21CFR Part 11 compliance, full integration
of UV and MS data and easy-to-use wizards allow defining methods
from acquisition to report generation required by the
biopharmaceutical industry. Data inspection is accelerated by
automatically generated and color coded analysis
assessments.
Biopharma Compass 2.0 unifies the data acquisition, data
analysis and result reporting of the most often used biopharma
workflows:
- Intact mass analysis of large proteins, antibodies or antibody
fragments to screen for and identify sequence errors or
post-translational modifications (PTM) quickly. Coupled with
Bruker's industry-leading SNAP-II algorithm for monoisotopic mass
determination (up to the heavy chain), this workflow delivers PTM
profiles quickly and with minimal experimental alteration.
- Top-down and middle-down screening of large proteins with both
ESI-UHR-QTOF and MALDI-TOF/TOF for sequence confirmation, and to
find protein N- or C-terminal modifications.
- Peptide screening with routine PTM and artifact quantification
with highest dynamic range, fully integrating LC-UV and MS, MS/MS
data in predefined report formats.
Biopharma Compass 2.0 wizard-driven workflows make it easy to
highlight common facets of monoclonal antibody and antibody-drug
conjugates (ADC) characterization, such as intact mass analysis,
sequence errors, truncations, substitutions, and key PTMs such as
glycosylation.
Dr. Rohan Thakur, Executive Vice
President at Bruker Daltonics, commented: "The wide dynamic range
of the maXis II ESI-UHR-QTOF system for large intact proteins and
their low abundance isoforms has provided a unique benefit to our
users trying to characterize mAbs. The exceptional
functionality and convenience offered by BPC 2.0 is a result of
co-developments with our biopharmaceutical customers to improve
their workflow efficiency."
To learn more, please attend the technical seminar on
Tuesday, January 24th,
2017 in the District Ballroom of the Mayflower Hotel in
Washington, D.C. to listen to Dr.
Jason Wood (Bruker) and Dr.
Kristin Boggio's (Pfizer,
Andover, MA) talk on 'Overcoming
challenges of intact biotherapeutics characterization with
ultra-high resolution mass spectrometers and the latest in
automated biopharmaceutical software'.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance scientific
research instruments and high-value analytical solutions enable
scientists to explore life and materials at molecular, cellular and
microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit www.bruker.com.
Investor
Contact:
|
Media
Contact:
|
Miroslava
Minkova
|
Dr. Petra
Scheffer
|
Bruker Head of
Investor Relations
|
Bruker Daltonics
Director of MarCom
|
T: +1 (978) 663–3660,
ext. 1479
|
T: +49 421 2205
2843
|
E:
miroslava.minkova@bruker.com
|
E:
petra.scheffer@bruker.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-announces-unique-and-comprehensive-workflows-for-biopharmaceutical-characterization-automated-by-biopharma-compass-20-300395501.html
SOURCE Bruker Corporation